CompletedNCT00571688
Risperidone injection or usual care to prevent bipolarity relapse
About this title
Read the official source — NCT00571688Medication studyAges 18–60United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- NashvilleSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Vanderbilt University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00571688
- Official title
Show the full official title
Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Nashville
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vanderbilt University, a university.
Did this study involve medication?
Yes. The study involved medication, including Risperdal (risperidone) Consta.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
